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ABSTRACT 
Objectives: To investigate the lignan derivatives potential as Plasmodium falciparum Lactate Dehydrogenase (PfLDH) inhibitors by using Computer 
Aided Drug Design (CADD) and molecular docking approach. 
Methods: In finding potential antiplasmodial, in silico approach has been utilized. Protein structure of PfLDH has been built through homology 
modeling. Kobamin has been used to refine the 3D PfLDH structure. Structure validation of PfLDH was done by Ramachandran Plot and ERRAT 
calculations. The validated PfLDH was ready for molecular docking analysis. lignan derivatives as lead compounds were designed. The 
pharmacophore of lignan derivatives were assessed by using Molsoft drug likeness. Both protein and Lignan derivatives were docked with 
Autodock Vina. The best docking score was shown by the lowest affinity energy. 
Results: Homology modeling of PfLDH has been built. Moreover, PfLDH refinement and validation were importantly conducted to ensure that 
PfLDH structure was in good quality. According to Ramachandran Plot and Procheck analysis, PfLDH has good structure quality with 93.39% 
confidence value. On the other hand, lignan derivatives assessment also has been done by evaluating their physicochemical and pharmacophore 
properties as lead compounds. From this assessment, it showed that Aristoligol (ARG1), Aristoligone (ARG2), and Ester Asetil Aristoligol (ARG3) 
showed good compounds to be drug likeness by following Lipinski’s rule of five (RO5), while Ester Butiril Aristoligol (ARG4) showed poor RO5 
criteria. Bioavailability of four compounds was good in body metabolism, however, ARG3 and ARG4 could not be lead like compounds due to poor 
lead likeness value. From molecular docking result, the most favorable binding with PfLDH was ARG4 based on its affinity energy value (-8.0 
kj/mol), followed by ARG3, ARG2 and ARG1, respectively. 
Conclusions: The identification of potential anti plasmodial drugs was successfully accomplished by evaluating synthetic lignan derivatives 
compound through physicochemical properties and molecular docking analysis. Overall, physicochemical and pharmacophore properties showed 
good result. Molecular docking interaction has distinct mode interactions of lignan derivatives with PfLDH. We believe that these evaluated 
compounds could be used as anti plasmodial drugs according to in silico evaluation results. 
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INTRODUCTION 
Malaria is one of the most invasive tropical diseases in the world 
especially in most developing countries which affecting mankind 
and constituting a major public health issue. It affects about 40% of 
the world’s population, or equal approximately 216 million 
individuals over tropical and subtropical areas of developing 
countries and causes mainly morbidity and mortality about 800,000 
death worldwide [1]. Moreover, approximately one third of the 
world’s population is at risk for exposing the disease. The World 
Health Organization (WHO) always strikes to actuate campaigns for 
global malaria eradication [2-4]. Malaria is a global important 
disease and worldwide burdens due to long-term limitations of 
vector control and the lack of an effective vaccine, makes therapeutic 
antimalarial drugs development becomes the serious main strategy 
to eliminate malaria [5]. 
The causative agents which responsible to malaria disease are 
protozoan parasites Plasmodium sp. In particular, Plasmodium 
falciparum has been known as the most deadly human malaria 
parasite, relies on the export of virulence factors to the surface of 
infected erythrocytes. Over the course of its intraerythrocytic 
developmental cycle (IDC), the pathogenicity of Plasmodium 
falciparum tightly affects the fluctuation of transcript levels for 
hundreds of genes [6-8]. P. falciparum lactate dehydrogenase 
(PfLDH) has been considered as a potential molecular drug target 
due to this parasite's dependence on glycolysis for energy 
production [9, 10]. Plasmodial lactate dehydrogenase is a terminal 
enzyme of the glycolytic pathway, has been shown to be 
biochemically, immunologically and structurally distinct from the 
mammalian enzyme [11]. Four Plasmodium species have been well 
known to infect human kind, including P. falciparum, P. vivax, P. 
ovale, and P. malariae. Moreover, P. knowlesi, has been recently 
documented to cause human malarial disease in Southeast Asia 
countries. Most severe diseases and deaths from malaria are caused 
by P. falciparum. It is responsible for about 80% of all malaria cases 
also responsible for about 90% of deaths caused by malaria [12-15]. 
By understanding a protein target mechanism in the parasite 
population is highly important to utilize it effectively in diagnostics 
and therapeutics [16]. The role of LDH in P. falciparum metabolism 
is a major checkpoint of anaerobic glycolysis, which form lactate 
from pyruvate reduction. This enzyme has recently become a great 
deal of attention as a valid therapeutic target for malaria disease. In 
fact, the P. falciparum’s isoform is a key enzyme for energy 
generation of malarial parasites. These species mostly depend on 
anaerobic glycolysis for energy production, since they lack a citric 
acid cycle for ATP formation. Therefore, PfLDH inhibition would 
potentially cause mortality of P. falciparum and it would be a great 
target to eradicate malaria [17]. Small new bioactive molecules have 
been recently designed and developed to inhibit target, PfLDH. 
Hence, inhibition of PfLDH may constitute an efficient way to 
develop therapeutic potentials [18-22]. 
Lignan derivatives are potential renewable sources as new anti-
malarial drugs, since they contain a quantity of metabolites with a 
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great variety of structures and pharmacological activities. 
Traditional preparations such as macerations, extracts, steam baths, 
concoctions, and decoctions from plant materials, have been the 
main source of malarial treatment in Indonesia and other 
developing countries where the disease is endemic [6,7]. Phoebe 
declinata Ness is a plant that has potential anti-malaria due to it 
contains Aristoligone lignan derivatives which have anti plasmodial 
activity in Holostylis reniformis plant [23]. However, the assessment 
of lignan derivatives to PfLDH is still unknown. The aim of this 
research is to investigate the lignan derivatives potential as PfLDH 
inhibitors by using molecular docking approach through Computer 
Aided Drug Design (CADD). The novelty of this study is finding the 
potential lignan derivatives which structurally modified against 
PfLDH. The main emphasis of this work is to identify the most 
potential drug candidates against PfLDH. We use high throughput 
platform such as pharmacophore properties [24, 25] and Lipinski’s 
rule of five [26] as complementary analysis in identifying the best 
lead compounds of lignan derivatives.  
MATERIALS AND METHODS 
Protein structure preparation 
The amino acid sequences of Pf LDH (Entry No. Q27743) was 
generated from UNIPROT protein database [27, 28]. The 3D 
structure of protein PfLDH was generated by web based SWISS-
MODEL program. All homology-modeling methods consist of the 
following four steps: (i) template selection; (ii) target template 
alignment; (iii) model building; and (iv) model evaluation. These 
steps are iteratively repeated, until a satisfying model structure is 
determined. The SWISS-MODEL server approach can be described as 
rigid fragment assembly [29-32].  
Protein structure refinement and validation 
PfLDH 3D structure was checked by using Procheck [33] to validate 
its refined structural conformation. Ramachandran plot [34-37] and 
ERRAT [38] were used to analyze the allowed dihedral phi and psi 
rotation of amino acids in the protein backbones and the quality of 
refined 3D structure, respectively.  
Lignan derivative structures preparation 
All four 3D lignan derivative structures were generated by Chem 
Draw Ultra 12.0 [39, 40] for the molecular docking experiments and 
their conformational energy were minimized by using MMFF94 
force field. Four molecules of lignan derivatives were designed by 
substituting the–R positions of lignan. These molecules are: 
Aristoligol (ARG1), Aristoligone (ARG2), Ester Asetil Aristoligol 
(ARG3), and Ester Butiril Aristoligol (ARG4), respectively. The 
molecule structures are depicted in fig. 1. The structures were 
scored based on their physicochemical properties under 
Chemicalize (Chem Axon) [41] and Molsoft [42] platforms. These 
physicochemical properties are important for developing the drug 
candidate in every stages from design to pre-clinical study.  
Molecular docking of Pf LDH-lignan derivative complexes 
The preparative protein and ligand coordinates were saved as pdb 
files. Molecular docking experiment is performed using Autodock 
Vina program (Vina, The Scripps Institute) [43]. The Autodock Tools 
is used to add partial charges using Gasteiger method and to arrange 
the polar hydrogens in the protein. The ligands are set to have 
flexible torsion angles at all rotatable bonds, while the protein is 
prepared as a rigid structure. Both protein and ligand are saved as 
output pdbqt files. For specific docking of ligand lignan derivatives 
onto the Pf LDH protein, the grid box volume was adjusted to 
40x40×40 Å in the x, y and z axes, respectively, with grid-sizes have 
a space up to 1 Å.  
The binding energy values were calculated based on the total 
intermolecular energies (kj/mol) including hydrogen bond energy, 
Van Der Waals energy, desolvation energy and electrostatic energy. 
On the other hand, the apropriate torsion angles of ligand are also 
induced as internal ligand energy. The docking program will 
evaluate this energy to obtain the best binding mode. The Root-
Mean-Square Deviation (RMSD) which less than 2.0 Å was scored 
during running docking program. 
RESULTS AND DISCUSSION 
Protein structure of PfLDH has been built from its amino acids 
sequence. Kobamin was used to refine PfLDH structure, showed 
better folding structure. PfLDH structure validation from 
Ramachandran plot (fig. 1) analysis proved that four amino acid 
residues with non-optimal values phi and psi have been located in 
alpha-and pi-turns of the LDH polypeptide chains, e. g., Asn1119, 
Asn75, Asn38 and Asn18.  
However, residues in most favored region is 87.8%, indicated a valid 
3D model structure (table 1). This validation was also supported by 
ERRAT analysis (fig.2). On the error axis, two lines are drawn to 
indicate the confidence of possible reject regions that exceed the 
error value. The ERRAT calculation is expressed as the percentage of 
the protein for which the calculated error value falls below the 95% 
rejection limit. Good high resolution structures generally produce 
values around 95% or higher. For lower resolution (2.5 to 3 Å) the 
average overall quality factor is around 91%. In this case, PfLDH 
structure with 93.39% was acceptable to be used for further in silico 
analysis through docking interaction. 
 
 
Fig. 1: Ramachandran Plot of PfLDH 
 
 
Fig. 2: ERRAT analysis of PfLDH 3D structure 
 
Table 1: Ramachandran plot summary 
Plot statistics Score Percent 
Residues in most favored regions [A,B,L] (red) 815 87.8% 
Residues in additional allowed regions [a,b,l,p] (yellow) 104 11.2% 
Residues in generously allowed regions [~a,~b,~l,~p] (pale yellow) 5 0.5% 
Residues in disallowed regions (white) 4 0.4% 
Number of non-glycine and non-proline residues 928 100% 
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One of lignan derivatives was drawn from natural Aristoligone. The 
other three derivatives were considered as synthetic structures 
which one–R group was synthesized to the different side chain (fig. 
3). In assessing the physicochemical and pharmacophore of lignan 
derivatives, we evaluate the lipophilicity of derivative compounds by 
using Chemicalize platform. This is a crucial parameter in drug 
development since it impacts both properties and target affinity of 
drug candidates. In early drug discovery stage, accurate tools for 
logP prediction are highly desired. LogP value is used to predict 
octanol/water partition coefficients of chemical compounds. Many 
calculation methods were developed to assist pharmaceutical areas 
in drug development. In this study, four compounds have logP 
values ranging from 4.65 to 6.06 (table 1). In general, an orally 
active drug has no more than one violation according to Lipinski`s 
rule of five, as followed criteria: 1. No more than 5 hydrogen bond 
donors (the total number of nitrogen–hydrogen and oxygen–hydrogen 
bonds); 2. No more than 10 hydrogen bond acceptors (all nitrogen or 
oxygen atoms); 3. A molecular mass less than 500 daltons; 4. An 
octanol-water partition coefficient; 5. logP not greater than 5 [44, 45]. 
From pharmacopore results showed that ARG1, ARG2 and ARG3 have 
followed Lipinski`s rule of five, but not ARG4 due to there were found 
more than two violations of Lipinski criteria. 
 
 
Fig. 3: Four Lignan derivative structures 
 
Table 2: Physicochemical and pharmacopore properties of lignan derivatives 
Compound Molecular formula Molecular weight Number of HBA/HBD pH LogP PSA (A2 Lipinski’s RO5 ) 
ARG1 C22 H28 O 372.45  5  5/1 7.4 3.64 57.15 Yes 
ARG2 C22 H26 O 370.18 5  5/0 7.4 3.90 53.99 Yes 
ARG3 C24 H30 O 414.20 6  6/0 7.4 4.08 63.22 Yes 
ARG4 C26 H34 O 442.24 6  6/0 7.4 5.22 63.22 No 
 
Table 3: Molecular docking interaction of lignan derivatives with PfLDH summary 
Compound Structure color Docking Affinity Energy (kj/mol)* Bioavailability Lead Likeness LogSw** 
ARG1 Red -7.4 Yes Yes -4.45 
ARG2 Blue -7.7 Yes Yes -5.32 
ARG3 Cyan -7.7 Yes No -4.82 
ARG4 Magenta -8.0 Yes No -5.73 
Notes: *Autodock Vina analysis, **Molsoft analysis 
 
 
Fig. 4: PfLDH-Lignan derivatives complex through molecular 
docking analysis, each compounds are colored differently 
(Green: PfLDH structure in folding ribbon, Red: ARG1, Blue: 
ARG2, Cyan: ARG3, Magenta: ARG4) 
 
Furthermore, drug likeness is also assessed relied on bioavailability, 
solubility and lead likeness, respectively (table 2). Drug likeness is a 
qualitative calculation used in drug design for how similar to drug a 
substance is with respect to factors like bioavailability. It is 
estimated from the molecular structure before the substance is even 
synthesized and tested.  
Molecules that violate more than one of Lipinski’s rules of five may 
have problems with bioavailability [46]. According to Veber rule, a 
good oral bioavailability should have Polar Surface Area (PSA) value 
less than 140 Å2 or less than 12 total hydrogen bonds (acceptors 
plus donors). The PSA values of lignan derivatives showed within 
the range of 57 to 64 Å2
47-49
 (table 2). Therefore, all lignan derivatives 
presented good bioavailability. Moreover, to have a good lead 
likeness, lead compounds should have LogSw (logarithm of water 
solubility) less than-5. From LogSw value, we could see that ARG1 
and ARG3 have LogSw less than-5, while ARG2 and ARG4 have 
LogSw more than-5. When synthetic lead compounds are planned to 
be modified for improving the water solubility or lead compounds 
permeability purpose, a wide parameter calculation of the structures 
could be used. It is important to clarify the structural modifications 
that increase solubility will also decrease drug permeability [ ]. 
 
 
Fig. 5: Lignan derivative modes inside the PfLDH cavity (Grey: 
PfLDH pocket structure in inner surface form, Red: ARG1, Blue: 
ARG2, Cyan: ARG3, Magenta: ARG4) 
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Three dimensional structure of PfLDH were built in SWISS Model 
web platform which its amino acids sequence was retrieved from 
UNIPROT, initially. Energy minimization of PfLDH protein structure 
was employed by using Kobamin refinement platform. included 
energy minimized and molecular dynamics simulations. The refined 
PfLDH was then used for docking interaction analysis. Autodock 
Vina was used for the docking studies. The docked conformation 
corresponding to the lowest binding energy was selected as the 
most favorable binding conformation. The total screened four 
compounds were docked into the active site of PfLDH. The docking 
energies of all the compounds were represented in kcal/mol. The 
best mode of protein-ligand complexes are shown on fig.4. Four 
lignan derivative compounds showed low binding energies and 
significant affinities with target PfLDH protein (table 3). All ligand 
conformers were embedded within the active site cavity of protein 
target. These favored ligand modes were stabilized by hydrogen 
bonds between the functional group from the ligands with the 
functional group of side chain residues of PfLDH protein (fig. 5). The 
best docked compounds were shown with the lowest affinity energy. 
From docking result, it is shown that ARG4 (-8.0 kj/mol) has the best 
binding interaction compared to ARG3 (-7.7 kj/mol), ARG2 (-7.7 
kj/mol) and ARG1 (-7.4 kj/mol), respectively (table 3). Relied upon 
this study, lignan derivatives compounds might be used as leads for 
developing effective antimalarial drugs. However, some poor 
bioavailability and pharmacopore could be structurally modified in 
the–R group to improve their bioactivities as lead compounds. 
CONCLUSION 
We have accomplished our investigation in identifying potential anti 
plasmodial drug candidates by evaluating synthetic lignan 
derivatives compound through physicochemical properties and 
molecular docking analysis. We suggested that all studied lignan 
derivative compound could be further validated in vivo and in vitro 
studies to confirm in silico evaluation. We believe that these 
evaluated compounds could be used as anti plasmodial drugs. 
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